The Laryngoscope

Hair Loss Without Scarring in Adults Using GLP-1 Medications: A Matched Group Study

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

GLP-1 receptor agonists may be associated with different subtypes of hair loss in adults with type 2 diabetes or obesity.

  • Hair loss outcomes linked to GLP-1 receptor agonists have not been thoroughly studied.
  • The evaluation focused on adults diagnosed with type 2 diabetes or obesity.
  • Different subtypes of hair loss were examined in relation to GLP-1 receptor agonist use.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Apr '26
GLP-1 Treatments and Hair Loss: Reviewing the Evidence and What It Means for Advice
systematic review
Jul '26
Real-world weight loss with different GLP-1 medicines in the All of Us study
top 20% journal
comparative study
May '26
How Drugs That Activate Glucagon-Like Peptide-1 Receptors May Be Linked to Hair Loss: Clinical Findings and Possible Causes
top 50% journal
journal article
Jul '25
Brain cell loss and stroke risk after Semaglutide and Tirzepatide in people with diabetes and obesity
top 2% journal
cited by 23 papers
research support, non-u.s. gov't
Aug '26
Hair Loss Linked to GLP-1 Receptor Agonists: Review of How Often It Happens, Types, Risks, and Possible Causes
top 50% journal
journal article
Aug '25
Weight Loss with Semaglutide and Tirzepatide in People with Overweight or Obesity Without Diabetes
top 20% journal
cited by 23 papers
journal article
Sep '24
Lower risk of repeated acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity who have had acute pancreatitis before
top 20% journal
cited by 19 papers
journal article
Mar '26
Factors linked to hair loss in people using GLP-1 receptor agonist medications
top 30% journal
cited by 1 paper
journal article
Jun '26
Real-world weight and blood sugar outcomes of tirzepatide versus semaglutide in people with obesity and type 2 diabetes
observational study
Jul '26
Cancer risk of weight-loss drugs that activate the glucagon-like peptide-1 receptor compared to bariatric surgery and other treatments
top 20% journal

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief